3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
6
Neuroendocrine Tumors
5
Neoplasm Metastasis
3
Carcinoma, Renal Cell
3
Tuberous Sclerosis
2
Triple Negative Breast Neoplasms
2
Recurrence
2
Glioma
2
Endometrial Neoplasms
2
Adenoma, Islet Cell
2
von Hippel-Lindau Disease
1
Vascular Malformations
1
Unilateral Breast Neoplasms
1
Thymus Neoplasms
1
Seizures
1
Sarcoma, Kaposi
1
Sarcoma
1
Nevus
1
Myelodysplastic Syndromes
1
Multiple Endocrine Neoplasia Type 1
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Meningioma
1
Lymphangioma
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Leiomyosarcoma
1
Kidney Neoplasms
1
Hemangioma
1
Hemangioendothelioma
1
Hamartoma Syndrome, Multiple
1
Interventions
pembrolizumab
3
Paclitaxel
2
Carboplatin
2
ulixertinib
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
selinexor
1
sapanisertib
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
dostarlimab
1
defactinib
1
dabrafenib
1
copanlisib
1
capivasertib
1
binimetinib
1
adavosertib
1
X-Rays
1
Vaginal Smears
1
VMBP protocol
1
Trastuzumab
1
Sutures
1
Sunitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Uterine Neoplasms
×
Everolimus
×
90 days
×
Clear all
No trials found.